Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009;1-146. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 14 April 2010]
   Google Scholar
• Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-59
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of boosted once-daily atazanavir and twice-daily lopinavir regimens in treatment-naïve HIV-1 infected subjects. CASTLE: 48-week results. Presented at the 15th Conference on Retroviruses and Opportunistic Infections (poster #37), Boston, 2008. Available at: http://img.thebody.com/confs/retro2008/slides/37%20Molina%20CASTLE%20Presentation.pdf. [Last accessed 2 December 2009]
   Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655
   PubMed Web of Science ®Google Scholar
• Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study. J Acquir Immune Defic Syndr 2010;53:323-332
   PubMed Web of Science ®Google Scholar
• Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-168
   PubMed Web of Science ®Google Scholar
• Worm SW, De Wit S, Weber R, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 2009;119:805-811
   PubMed Web of Science ®Google Scholar
• American Heart Association. Heart Disease and Stroke Statistics – 2009 Update. Dallas, Texas: American Heart Association; 2009
   Google Scholar
• Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004;5:294-304
   PubMed Web of Science ®Google Scholar
• Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-765
   PubMed Web of Science ®Google Scholar
• National Vital Statistics Report Volume 56, Number 10. Deaths: Final data for 2005. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_10.pdf. [Last accessed 8 December 2009]
   Google Scholar
• Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007;23:1505-1514
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-1183
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: the D:A:D CHD Risk Equation. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California
   Google Scholar
• Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-660
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Burnett CK, Cook EW 3rd, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996;41:2248-2253
   PubMed Web of Science ®Google Scholar
• Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001;134:860-868
   PubMed Web of Science ®Google Scholar
• Ingenix National Fee Analyzer 2008
   Google Scholar
• PriceRx Wolters Kluwer Health 2009
   Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718
   PubMed Web of Science ®Google Scholar
• Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts. Infection 2009;37:244-249
   PubMed Web of Science ®Google Scholar
• Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006;44:990-997
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. New York, NY: Oxford University Press, 2005
   Google Scholar
• Dale W, Basu A, Elstein A, et al. Predicting utility ratings for joint health states from single health states in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making 2008;28:102-112
   PubMed Web of Science ®Google Scholar
• Fu AZ, Kattan MW. Utilities should not be multiplied: evidence from preference-based scores in the United States. Med Care 2008;46:984-990
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics, U.S. Department of Labor. CPI Detailed Report: Data for May 2009. Crawford M, Katz S, eds. www.bls.gov/cpi/cpid0905.pdf. Accessed June 30, 2009
   Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641
   PubMed Web of Science ®Google Scholar
• King JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005;25:667-677
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-528
   PubMed Web of Science ®Google Scholar
• Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health 2007;28:365-391
   PubMed Web of Science ®Google Scholar
• King JT Jr, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005;25:667-677
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Skinner JA. Comparative effectiveness and health care spending–implications for reform. N Engl J Med 2010;362:460-5. Epub 2010 Jan 6
   PubMed Web of Science ®Google Scholar
• Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir + ritonavir regimens in the CASTLE study. Adv Ther 2009;26:185-193
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo MP, Chumney EC, et al. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Invest 2007;27:67-74
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003;17:1741-1751
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-694
   PubMed Web of Science ®Google Scholar